Results 91 to 100 of about 34,423 (243)

Optimizing Lymph Node Staging in Gallbladder Cancer: A Cutoff of 11 Nodes for Accurate Staging and Improved Survival

Journal of Hepato-Biliary-Pancreatic Sciences, EarlyView.
ABSTRACT Background Gallbladder cancer (GBC) is an aggressive malignancy in which lymph node (LN) status is a key prognostic factor. Adequate LN retrieval is essential for accurate nodal staging. This study aimed to identify an LN threshold that reduces false node‐negative (false N0) rates and to evaluate its association with overall survival (OS) as ...
So Jeong Yoon, Hyun Jeong Jeon, Boram Park, Hyeong Seok Kim, Hochang Chae, Sang Hyun Shin, In Woong Han, Jin Seok Heo, Okjoo Lee, Hongbeom Kim   +9 more
wiley   +1 more source

Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial [PDF]

, 2017
BACKGROUND: The ESPAC-3 trial showed that adjuvant gemcitabine is the standard of care based on similar survival to and less toxicity than adjuvant 5-fluorouracil/folinic acid in patients with resected pancreatic cancer.
Akaike, Alan Anthoney, Alec McDonald, Bengt Glimelius, Campbell, Capello, Christopher M Halloran, Conroy, Cox, Cunningham, Daniel H Palmer, David Borg, David Cunningham, David Sherriff, Derek A O'Reilly, Eftychia E Psarelli, Gary William Middleton, Greenhalf, Harpreet Wasan, Henderson, Jakob R Izbicki, John P Neoptolemos, Jonathan Wadsley, Juan W Valle, Kinnari Patel, Kleeff, Liao, Markus W Büchler, Neoptolemos, Neoptolemos, Neoptolemos, Neoptolemos, Neoptolemos, Oettle, Olusola Faluyi, Pascal Hammel, Paul J Ross, Paula Ghaneh, Pehr Lind, Peto, Peto, Reni, Richard Jackson, Roopinder Gillmore, Rubin Soomal, Schemper, Schoenfeld, Sebastian Cummins, Sharmila Sothi, Sinn, Stephen Falk, Sultana, Suzanne Darby, Thilo Hackert, Tim Meyer, Tom Crosby, Trotti, Uesaka, Valle, Vivaldi, Von Hoff, White, Yuk Ting Ma   +62 more
core   +6 more sources

Phase IIb Trial for the Palliative Treatment of Patients With Primary Hepatic Malignancy Unable to Receive Curative Treatment: Efficacy of Colchicine

The Kaohsiung Journal of Medical Sciences, EarlyView.
ABSTRACT This trial was to evaluate the efficacy and the safety of colchicine for the palliative treatment of patients with primary hepatic malignancy unable to receive curative treatment. Forty hepatocellular carcinoma (HCC) patients and two intrahepatic cholangiocarcinoma (ICC) patients signed the informed consents.
Zu‐Yau Lin, Ming‐Lun Yeh, Po‐Cheng Liang, Shinn‐Cherng Chen, Chung‐Feng Huang, Jee‐Fu Huang, Chia‐Yen Dai, Ming‐Lung Yu, Wan‐Long Chuang   +8 more
wiley   +1 more source

Prognostic role of inflammatory and tumor biomarkers in hilar cholangiocarcinoma patients receiving postoperative adjuvant therapy

Frontiers in Oncology
BackgroundHilar cholangiocarcinoma (HCCA) is an aggressive cancer with poor prognosis after surgery. The systemic immune-inflammation index (SII) has been proposed as a prognostic marker, but its relationship with other markers such as CA19-9 remains ...
Di Zeng, Di Zeng, Saud Ahmad Saad, Saud Ahmad Saad, Zhen You, Zhen You, Nansheng Cheng, Nansheng Cheng   +7 more
doaj   +1 more source

Diagnostic Role of CA19-9, CA19-9/CRP Ratio and CA19-9/Total Bilirubin Ratio in Differentiating Benign and Malignant Obstructive Jaundice

Bangladesh Journal of Medicine
Background: Serum carbohydrate antigen (CA19-9) is a tumour marker which is significantly elevated in biliary and pancreatic malignancy. It is also increased in some benign conditions associated with jaundice. So many strategies have been recommended to improve the power of CA 19-9 to differentiate benign and malignant obstructive jaundice.
Mohammad Golam Azam, Ali Arbab Chowdhury, Sarker Mohammed Sajjad, Indrajit Kumar Datta, Md Anisur Rahman, AHM Rowshon   +5 more
openaire   +1 more source

Liquid Biopsy Differentiation of Pancreatic Cancer From Non‐Cancerous Pancreatic Disease Using Dielectrophoresis‐Recovered Nanoparticles Carrying Cell‐Free DNA and Protein Biomarkers

Small, EarlyView.
A new nanoparticle‐based biomarker panel is described that can differentiate pancreatic cancer from benign pancreatic disease with a high level of performance. This was enabled by microelectrode array recovery technology that used dielectrophoresis (DEP) to quickly and efficiently recover the nanoparticles from patient plasma samples, followed by on ...
Anna Malakian, Augusta Modestino, Jesus Bueno, Archana Machireddy, Jason Ware, Sean Hamilton, Ella Stimson, Sarah Mitchell, Joshua C. Saldivar, Ashley R. Woodfin, Corey M. Dambacher, Kyle Gustafson, Delaney Shea, Srivathsan Ranganathan, Mehrzad Sasanpour, Christian Ross, Dove Keith, Jeong Youn Lim, Xubo Song, Scott M. Lippman, Rosalie Sears, Terry Morgan, Michael Heller, Stuart D. Ibsen   +23 more
wiley   +1 more source

Prognostic and therapeutic significance of carbohydrate antigen 19-9 as tumor marker in patients with pancreatic cancer [PDF]

, 2006
In pancreatic cancer ( PC) accurate determination of treatment response by imaging often remains difficult. Various efforts have been undertaken to investigate new factors which may serve as more appropriate surrogate parameters of treatment efficacy ...
Anderson JS, Bekaii-Saab TS, Brambs HJ, Burris HA, Ebrahimi B, Glenn J, Gogas H, Goggins M, Heinemann V, Heinemann V, Heinemann V, Ishii H, Jamieson NB, Jiang XT, Katz A, Ko AH, Koprowski H, Louvet C, Lundin J, Maisey NR, Montgomery RC, Moore MJ, Ni XG, Okusaka T, Petra Stieber, Philip PA, Ralf Wilkowski, Saad ED, Safi F, Safi F, Sakar B, Sawaki A, Sperti C, Stathopoulos GP, Stefan Boeck, Stefan Holdenrieder, Steinberg W, Tanaka N, Tempero MA, Tian F, van Custem E, Vimalachandran D, Volker Heinemann, Wilkowski R, Wilkowski R, Wilkowski R, Willet CG, Wolff RA, Ziske C   +48 more
core   +1 more source

IMMUNOHISTOLOGICAL STUDIES OF TUMOR MARKER CA19-9

The journal of the Japanese Practical Surgeon Society, 1989
Immunohistological examination of tumor tissues using monoclonal antibody CA19-9 was performed in 20 cases including 4 pancreatic cancer, 6 bile duct cancer, 4 gastric cancer, 3 papillary cancer, 1 duodenal cancer, 1 colon cancer and 1 ovarian teratoma.
Seiichiro ANDOH, Masayuki ITAKURA, Takahiko NOHARA, Keiji ONO, Tatsuyuki SESHIMO, Akira NAKASE   +5 more
openaire   +2 more sources

Whole‐transcriptome sequencing analyses identified exosomal circular RNAs in the plasma of pancreatic cancer patients as novel blood‐based biomarkers of disease

VIEW, EarlyView.
Pancreatic cancer (PaCa) has a poor prognosis, with low resection rates and high relapse rates, highlighting the urgent need for novel diagnostic biomarkers. Here, we performed whole‐transcriptome sequencing of plasma‐derived exosomes from PaCa patients and identified several differentially expressed circular RNAs (circRNAs).
Xiaomeng He, Yang Di, Lixiang Sun, Zhirong Wu, Mengting Luo, Xin Zhang, Huaqin Sun, Wanli Xu, Wenchuan Wu, Boheng Zhang, Jin Wang   +10 more
wiley   +1 more source

CA19–9 decrease and survival according to platelet level in patients with advanced pancreatic cancer

BMC Cancer, 2019
Background CA19–9 decrease during treatment has been associated with superior survival of pancreatic cancer in several studies. The evidence to show the correlation of high platelet level with inferior survival is insufficient in pancreatic cancer.
Y. Chen, Y. R. Wang, G. C. Deng, G. H. Dai   +3 more
doaj   +1 more source